Literature DB >> 12114662

Adrenocorticotropin-Producing Pituitary Carcinoma with Expression of c-erbB-2 and High PCNA Index: A Comparative Study with Pituitary Adenomas and Normal Pituitary Tissues.

Vania Nose-Alberti1, Maria Isabel S. Mesquita, Luciana C. Martin, Marcia J. Kayath.   

Abstract

Pituitary carcinomas are very rare neoplasms with a poor prognosis. We report a case of Cushing's disease resulting from a pituitary carcinoma in a 22-yr old female, who died of massive hepatic failure. At autopsy, there was invasion of the parasellar structures and vasculature by the tumor, which stained positively only for ACTH. There were two metastatic nodules in the liver, which also stained positively for ACTH. When compared to other cases of Cushing's disease (n = 52), other pituitary adenomas (n = 292). and normal pituitary tissues (n = 21), the pituitary carcinoma was the only one with c-erbB-2 membrane staining in both the sellar-located tissue and liver metastasis. C-erbB-2 staining was present in the cytoplasm of a variable number of cells in 40% of the invasive adenomas (n = 103), while only 1.2% of the noninvasive tumors (n = 241) expressed this protein (p < 0.001). No particular immunohistological type preferentially expressed this protein. In normal pituitary tissues, 10% of the cells expressed cytoplasmic c-erbB-2. A higher index of proliferating cell nuclear antigen (PCNA) in the primary tumor and liver metastasis (10%) was also found compared to other ACTH-secreting adenomas (invasive, 3.4 -t 1 S% vs 1 ii +/- 1.5% in noninvasive) and other pituitary tumors (invasive, 2.9 +/- 1.5% vs 1.5 +/- 1.3% in noninvasive). The PCNA index was significantly higher in invasive tumors than in noninvasive adenomas (p = 0.004). PCNA staining was negative in normal pituitary tissues. Staining for p53, pRB and p(2ras) was negative in the carcinoma and liver metastasis. We suggest that the c-erbB-2 membrane pattern and a higher PCNA index may indicate a worse prognosis in adenohypophyseal neoplasia.

Entities:  

Year:  1998        PMID: 12114662     DOI: 10.1007/bf02739952

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  57 in total

1.  Abundance and state of phosphorylation of the retinoblastoma gene product in human pituitary tumors.

Authors:  M Woloschak; A Yu; J Xiao; K D Post
Journal:  Int J Cancer       Date:  1996-07-03       Impact factor: 7.396

2.  p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions.

Authors:  K Thapar; B W Scheithauer; K Kovacs; P J Pernicone; E R Laws
Journal:  Neurosurgery       Date:  1996-04       Impact factor: 4.654

3.  Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer.

Authors:  M J van de Vijver; J L Peterse; W J Mooi; P Wisman; J Lomans; O Dalesio; R Nusse
Journal:  N Engl J Med       Date:  1988-11-10       Impact factor: 91.245

Review 4.  Genetic basis of endocrine disease: pituitary tumor pathogenesis.

Authors:  I Shimon; S Melmed
Journal:  J Clin Endocrinol Metab       Date:  1997-06       Impact factor: 5.958

5.  Cushing's disease due to pituitary carcinoma.

Authors:  M S Zafar; R C Mellinger; J L Chason
Journal:  Henry Ford Hosp Med J       Date:  1984

6.  The c-erbB-2/neu proto-oncogene in human pituitary tumours.

Authors:  S Ezzat; L Zheng; H S Smyth; S L Asa
Journal:  Clin Endocrinol (Oxf)       Date:  1997-05       Impact factor: 3.478

7.  Prognostic significance of the overexpression of c-erbB-2 protein in adenocarcinoma of the uterine cervix.

Authors:  T Kihana; H Tsuda; S Teshima; K Nomoto; S Tsugane; T Sonoda; S Matsuura; S Hirohashi
Journal:  Cancer       Date:  1994-01-01       Impact factor: 6.860

Review 8.  [Primary carcinoma of the pituitary gland with Cushing's syndrome and metastases. Apropos of a case with review of the literature].

Authors:  H Lévesque; P Fréger; A Gancel; J Tayot; H Courtois
Journal:  Rev Med Interne       Date:  1991 May-Jun       Impact factor: 0.728

9.  Ras mutations in human pituitary tumors.

Authors:  H J Karga; J M Alexander; E T Hedley-Whyte; A Klibanski; J L Jameson
Journal:  J Clin Endocrinol Metab       Date:  1992-04       Impact factor: 5.958

10.  Expression of epidermal growth factor (EGF), its receptor, and related oncoprotein (erbB-2) in human pituitary tumors and response to EGF in vitro.

Authors:  S S Chaidarun; M C Eggo; M C Sheppard; P M Stewart
Journal:  Endocrinology       Date:  1994-11       Impact factor: 4.736

View more
  17 in total

1.  Abstracts of the 8th International Pituitary Pathology Meeting. October 5-9, 2001. Greece.

Authors: 
Journal:  Endocr Pathol       Date:  2001       Impact factor: 3.943

Review 2.  Expression and function of ErbB receptors and ligands in the pituitary.

Authors:  Odelia Cooper; George Vlotides; Hidenori Fukuoka; Mark I Greene; Shlomo Melmed
Journal:  Endocr Relat Cancer       Date:  2011-10-27       Impact factor: 5.678

Review 3.  Role of tyrosine kinase inhibitors in the treatment of pituitary tumours: from bench to bedside.

Authors:  Anat Ben-Shlomo; Odelia Cooper
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2017-08       Impact factor: 3.243

Review 4.  Pituitary carcinoma: report of an exceptional case and review of the literature.

Authors:  C Pichard; S Gerber; M Laloi; M Kujas; S Clemenceau; D Ponvert; E Bruckert; G Turpin
Journal:  J Endocrinol Invest       Date:  2002-01       Impact factor: 4.256

5.  ErbB receptor-driven prolactinomas respond to targeted lapatinib treatment in female transgenic mice.

Authors:  Xiaohai Liu; Maya Kano; Takako Araki; Odelia Cooper; Hidenori Fukuoka; Yukiko Tone; Masahide Tone; Shlomo Melmed
Journal:  Endocrinology       Date:  2015-01       Impact factor: 4.736

6.  Prolactinoma ErbB receptor expression and targeted therapy for aggressive tumors.

Authors:  Odelia Cooper; Adam Mamelak; Serguei Bannykh; John Carmichael; Vivien Bonert; Stephen Lim; Galen Cook-Wiens; Anat Ben-Shlomo
Journal:  Endocrine       Date:  2013-11-28       Impact factor: 3.633

7.  An Institutional Experience of Tumor Progression to Pituitary Carcinoma in a 15-Year Cohort of 1055 Consecutive Pituitary Neuroendocrine Tumors.

Authors:  Omalkhaire M Alshaikh; Sylvia L Asa; Ozgur Mete; Shereen Ezzat
Journal:  Endocr Pathol       Date:  2019-06       Impact factor: 3.943

8.  Malignant prolactinoma with craniospinal metastasis in a 12-year-old boy.

Authors:  Abel Po-Hao Huang; Shih-Hung Yang; Chi-Cheng Yang; Meng-Fai Kuo; Mu Zon Wu; Yong-Kwang Tu
Journal:  J Neurooncol       Date:  2008-07-12       Impact factor: 4.130

9.  Heregulin regulates prolactinoma gene expression.

Authors:  George Vlotides; Odelia Cooper; Yen-Hao Chen; Song-Guang Ren; Yona Greenman; Shlomo Melmed
Journal:  Cancer Res       Date:  2009-04-28       Impact factor: 12.701

Review 10.  Malignant pituitary corticotroph adenomas: report of two cases and a comprehensive review of the literature.

Authors:  Agatha A van der Klaauw; Tina Kienitz; Christian J Strasburger; Johannes W A Smit; Johannes A Romijn
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.